This is a working overview of WADA, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a PPARδ agonist. |
| Typical detection matrix | Urine | Most common sample for anti-doping analysis. |
| Common analytical method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry. |
| Common synonyms | GW501516, GSK-516, endurobol | Names found in research and fitness contexts. |
| Typical detection window | Variable | Depends on dose, route, and individual metabolism. |
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
==== Fatal infantile-onset phenotype ==== There is an ultra-rare, fatal infantile-onset phenotype that results in profound muscle weakness ("floppy baby") and respiratory failure within weeks of birth (perinatal asphyxia). Post-mortem biopsy showed a deficiency of myophosphorylase and abnormal glycogen accumulation in skeletal muscle tissue. This phenotype may also include premature birth and joint contractures. Two reported cases, in 1978 and 1989.
=== Visual Effects === The Lord of the Rings: The Fellowship of the Ring (2001) (lead massive crowd technical director) The Lord of the Rings: The Two Towers (2002) (senior massive technical director) The Matrix Reloaded (2003) (lead technical director) The Matrix Revolutions (2003) (sentinel/swarm lead) The Lord of the Rings: The Return of the King (2003) (senior massive technical director) Catwoman (2004) (CG supervisor) Drawing Restraint 9 (2005) (lead technical director) Pirates of the Caribbean: Dead Man's Chest (2006) (digital artist)
The vegetative body of the lichen, the thallus, is foliose (leafy) and typically less than 8 centimetres (3.1 in) wide. The lobes of the thallus are 1–4 mm (rarely up to 7 mm) in diameter, and flattened, though in African populations the lobes tend to be smaller than those in temperate areas, typically 0.5–2.0 mm wide. The upper surface is some shade of yellow, orange, or greenish yellow, becoming almost green when growing in shaded situations. The lower surface is white, has a cortex, and sparse pale rhizines or hapters that help attach the thallus to its substrate. The vegetative reproductive structures soredia and isidia are absent in this species. X. parietina reproduces primarily through sexual reproduction via apothecia (fruiting bodies). Apothecia typically develop about 2–4 mm behind the growing edge of the thallus and take 12–18 months to reach maturity. Mature apothecia typically measure between 1.5 and 2.6 mm in diameter, though in rare cases they can reach up to 4.3 mm. They can comprise between 0–87% of a thallus's dry weight, with most thalli dedicating 10–30% of their biomass to these reproductive structures. The apothecia can release spores at rates of up to 50 per minute under humid conditions. The production of apothecia appears to be independent of the thallus's directional aspect (north, south, east, or west facing), meaning that sunlight exposure does not significantly influence reproductive effort.
Sources: en.wikipedia.org
Villa Erica (Heather Villa): suggesting a Romano-British origin Bellerīca: a medieval Latin word meaning 'dyehouse or tanhouse' Billers: a traditional name for watercress, for which Bilbrook in Somerset and Staffordshire are named. Watercress was farmed in Billericay springs during the 20th century. Although the precise etymology of the name is not known, England has places similarly named:
In chemistry and biology, reactive oxygen species (ROS) are highly reactive chemicals formed from diatomic oxygen (O2), water, and hydrogen peroxide. Some prominent ROS are the hydroperoxide radical or hydroperoxyl (HO2), superoxide (O2−), the hydroxyl radical (OH.), and singlet oxygen (1O2). ROS are pervasive because they are readily produced from O2, which is abundant. Biologically, ROS function as cell signals, are intermediates in the redox behavior of O2, and impact the process of aging.
The acetyl group of acetylornithine is removed by the enzyme acetylornithinase (AO) or ornithine acetyltransferase (OAT), and this yields ornithine. Then, the enzymes citrulline and argininosuccinate convert ornithine to arginine.
== Clinical trials == ACD856 has completed phase 1 clinical trials for Alzheimer's disease. As of May 2024, it was in the preclinical stage of development for depressive disorders, sleep disorders, and traumatic brain injuries. Two phase 1 trials had been completed by 2022. A further phase 1b trial, assessing the safety and tolerability of repeated higher doses, reached its last patient visit in April 2026, and results were reported in June 2026. A phase 2 clinical trial in Alzheimer's disease was expected to start in 2026, supported by a €2.5 million European Innovation Council Accelerator grant awarded in 2025. The drug was developed by AlzeCure Pharma AB, which in July 2026 out-licensed worldwide rights to ACD856 and the NeuroRestore platform to the Danish company QuantumCell ApS for US$12 million upfront, with development and commercial milestone payments that could exceed US$2.2 billion.
Sources: en.wikipedia.org
Immunosuppressants Non-steroidal anti-inflammatory drugs (NSAIDs) and salicylates Inhibitors of thyrosine kinases Opiates Treatment for benign prostatic hyperplasia Hormonal treatments and antiadrenergic drugs Antibiotics, antifungals, antiparasites, antivirals, and antimalarials Antidepressants Anti-gastroesophageal reflux drugs Anti-epileptic drugs Antihypertensive drugs Certain medications in the following classes of drugs may affect male sexual libido or sexual function**:
The club reached the final of the Coupe de France, the national knockout cup competition in the same season, but lost 4–3 to Marseille. Monaco again finished third in 1989–90; striker Ramón Díaz scored 15 goals in his first season at the club. The club beat league winners Marseille in the Coupe de France final through a last-minute goal from substitute Gérald Passi. In 1991–92, Monaco finished in second place and lost the 1992 European Cup Winners' Cup Final 2–0 to Werder Bremen. Although Monaco acquired the services of German striker Jürgen Klinsmann, the club could not regain the championship and concluded the subsequent seasons in third and ninth positions. Monaco did reach the semi-finals of the Champions League in April 1994, but lost to eventual winners Milan. As a result of his work at Monaco, Wenger was sought after by German club Bayern Munich, who wanted him to be their next manager. Monaco refused to let him leave and Wenger chose to stay, but a poor start to the 1994–95 season meant he was dismissed on 17 September 1994, with the team in 17th spot in the table. In 2001, Wenger said that the impact of bribery and corruption had influenced his decision to leave France, as Marseille were found guilty of match fixing in 1994.
The new 26th district is based in the northwestern corner of the Dallas–Fort Worth metroplex, centering on southern and eastern Denton County (including the county's share of Carrollton along with all of Lewisville, Flower Mound and Little Elm) and including Cooke County (Gainesville) and the southern two-thirds of Wise County including Decatur. The incumbent is Republican Brandon Gill, who was elected with 62.1% of the vote in 2024. That same year, the district gave 61.2% of the vote to Donald Trump and 58.4% to Ted Cruz.
Decreased size of head Sensorineural deafness Also, most of the patients experience so called "TANGO2 spells", which include episodes of difficulty in maintaining the position of the head, salivation, exhaustion, and decreased alertness and it can be triggered by fasting, dehydration, exposure to excessive heat, infections, and ketogenic diet.
== Interactions == Bempedoic acid does not interact with the cytochrome P450 enzyme system in the liver and only weakly inhibits the transporter proteins SLCO1B1, SLCO1B3 and SLC22A7 (the latter possibly being responsible for the increase of uric acid in the blood, and therefore the adverse effect gout). Despite this, the drug increases blood levels of statins. The effect is most pronounced with simvastatin and pravastatin, whose AUC is increased about twofold. No other clinically relevant interactions have been found in studies.
Sources: en.wikipedia.org
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.
Detection usually uses liquid chromatography-tandem mass spectrometry after sample cleanup. Laboratories look for the parent compound or metabolites. The method requires validated reference standards and controls.
Legality varies by country. In many places it is an unapproved drug and cannot be legally sold for human consumption. Purchasing from online vendors carries legal and quality risks.
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.